The most important thing in real estate is "location, location, location" -- but in the pharmaceutical industry it's "innovation, innovation, innovation." Drugmaker AstraZeneca (NYSE:AZN) is grappling with the effects of some massive drug patent expirations and is under pressure to innovate quickly. The week, the company's recently appointed CEO changed up both personnel and structure in his management team. In this video, our health-care analysts discuss these changes and how they might jump-start an R&D revolution at the company.
David Williamson, Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Snapchat Will Bring In More U.S. Ad Revenue Than Twitter This Year
Snapchat has long been Twitter's biggest threat, but Snapchat faces threats itself.
Here's How Phillips 66 Crushed It in 2017
But there are signs that the oil industry player's outperformance trend may not last long into 2018.
Hate Checking Your Portfolio? Try These 2 High-Yield Stocks
If you agree with the notion that boring is good, then check out this energy company and this petroleum pipeline operator.